Sagimet Biosciences (SGMT) News Today → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free SGMT Stock Alerts $4.38 +0.14 (+3.30%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 7, 2024 | finance.yahoo.comSagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024May 6, 2024 | marketwatch.comSagimet Biosciences Names Thierry Chauche Chief Financial OfficerMay 6, 2024 | finanznachrichten.deSagimet Biosciences Inc.: Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial OfficerMay 6, 2024 | globenewswire.comSagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial OfficerMay 6, 2024 | americanbankingnews.comSagimet Biosciences (NASDAQ:SGMT) Now Covered by HC WainwrightMay 6, 2024 | americanbankingnews.comSagimet Biosciences Inc. Expected to Post Q1 2024 Earnings of ($0.41) Per Share (NASDAQ:SGMT)May 2, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Sagimet Biosciences (SGMT) with Buy RecommendationMay 2, 2024 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Coverage Initiated at HC WainwrightHC Wainwright initiated coverage on Sagimet Biosciences in a research note on Thursday. They set a "buy" rating and a $32.00 target price for the company.April 22, 2024 | globenewswire.comSagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024April 13, 2024 | marketbeat.comShort Interest in Sagimet Biosciences Inc. (NASDAQ:SGMT) Expands By 31.3%Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,350,000 shares, a growth of 31.3% from the March 15th total of 1,790,000 shares. Currently, 19.4% of the company's stock are sold short. Based on an average trading volume of 1,710,000 shares, the days-to-cover ratio is presently 1.4 days.March 29, 2024 | insidertrades.comDavid Happel Buys 12,100 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) StockMarch 29, 2024 | marketbeat.comLeerink Partnrs Equities Analysts Boost Earnings Estimates for Sagimet Biosciences Inc. (NASDAQ:SGMT)Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Research analysts at Leerink Partnrs boosted their Q1 2024 earnings per share estimates for shares of Sagimet Biosciences in a research report issued to clients and investors on Tuesday, March 26th. Leerink Partnrs analyst T. Smith now expectMarch 28, 2024 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) CEO David Happel Acquires 12,100 SharesSagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) CEO David Happel bought 12,100 shares of the firm's stock in a transaction on Tuesday, March 26th. The stock was bought at an average price of $5.27 per share, with a total value of $63,767.00. Following the completion of the purchase, the chief executive officer now owns 639,200 shares of the company's stock, valued at $3,368,584. The purchase was disclosed in a legal filing with the SEC, which is available at this link.March 28, 2024 | finance.yahoo.comSagimet Biosciences Inc (SGMT) Reports Full Year 2023 Financial Results: A Close LookMarch 27, 2024 | globenewswire.comSagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor DenifanstatMarch 26, 2024 | marketbeat.comThe Goldman Sachs Group Trims Sagimet Biosciences (NASDAQ:SGMT) Target Price to $27.00The Goldman Sachs Group cut their price target on shares of Sagimet Biosciences from $37.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday.March 25, 2024 | markets.businessinsider.comStrong Buy Recommendation: Sagimet Biosciences’ Unique NASH Drug and Solid Financials Signal Market Growth PotentialMarch 25, 2024 | markets.businessinsider.comSagimet Biosciences: Strong Buy on Robust Financials and Promising NASH Drug TrialsMarch 25, 2024 | msn.comSagimet Biosciences GAAP EPS of -$2.66 beats by $34.65, revenue of $2M in-lineMarch 25, 2024 | marketbeat.comSVB Leerink Initiates Coverage on Sagimet Biosciences (NASDAQ:SGMT)SVB Leerink began coverage on shares of Sagimet Biosciences in a research note on Monday. They issued an "outperform" rating and a $26.00 price target on the stock.March 25, 2024 | globenewswire.comSagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of DirectorsMarch 25, 2024 | globenewswire.comSagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 6, 2024 | marketbeat.comRTW Investments LP Invests $3.52 Million in Sagimet Biosciences Inc. (NASDAQ:SGMT)RTW Investments LP acquired a new stake in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 400,277 shares of the company's stock, valued at approxMarch 5, 2024 | marketbeat.com738,355 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by Rock Springs Capital Management LPRock Springs Capital Management LP purchased a new position in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 738,355 shares of the company's stockMarch 3, 2024 | marketbeat.comShort Interest in Sagimet Biosciences Inc. (NASDAQ:SGMT) Grows By 44.4%Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 1,560,000 shares, an increase of 44.4% from the January 31st total of 1,080,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 12.9% of the company's stock are short sold.February 29, 2024 | globenewswire.comSagimet Biosciences to Participate in Two Upcoming Investor ConferencesFebruary 25, 2024 | benzinga.comSagimet Biosciences Stock (NASDAQ:SGMT) Dividends: History, Yield and DatesFebruary 24, 2024 | msn.comSagimet Biosciences (SGMT) Price Target Increased by 17.19% to 51.00February 23, 2024 | finance.yahoo.comPainful week for retail investors invested in Sagimet Biosciences Inc. (NASDAQ:SGMT) after 22% drop, institutions also suffered lossesFebruary 18, 2024 | marketbeat.com100,000 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by Silverarc Capital Management LLCSilverarc Capital Management LLC acquired a new position in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 100,000 shares of the company's stock, valued at approximately $880,000.February 17, 2024 | morningstar.comSagimet Biosciences Inc Class A Shares SGMTFebruary 7, 2024 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) PT Lowered to $46.00JMP Securities reduced their target price on shares of Sagimet Biosciences from $47.00 to $46.00 and set a "market outperform" rating for the company in a research report on Wednesday.February 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sagimet Biosciences as Phase 2b Results of Denifanstat Outshine CompetitorsFebruary 6, 2024 | realmoney.thestreet.comSagimet Biosciences price target lowered by $1 at JMP Securities, here's whyFebruary 6, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Sagimet Biosciences IncFebruary 3, 2024 | msn.comSagimet Biosciences Announces Interim CFO AppointmentJanuary 30, 2024 | uk.finance.yahoo.comSagimet Biosciences Inc. (SGMT)January 26, 2024 | msn.comSagimet Biosciences prices public offering of 9M shares at $12.50 per shareJanuary 26, 2024 | finance.yahoo.comSagimet Biosciences Announces Pricing of Public Offering of Series A Common StockJanuary 23, 2024 | markets.businessinsider.comSagimet Biosciences Announces Proposed Public Offering of Series A Common StockJanuary 23, 2024 | finance.yahoo.comSagimet Biosciences Announces Proposed Public Offering of Series A Common StockJanuary 23, 2024 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Given New $37.00 Price Target at The Goldman Sachs GroupThe Goldman Sachs Group boosted their price objective on Sagimet Biosciences from $30.00 to $37.00 and gave the stock a "buy" rating in a research note on Tuesday.January 22, 2024 | realmoney.thestreet.comSagimet Biosciences price target raised to $47 from $31 at JMP SecuritiesJanuary 22, 2024 | msn.comSagimet Biosciences Stock (NASDAQ:SGMT): Don’t Get Squeezed Out of Your MoneyJanuary 22, 2024 | marketbeat.comJMP Securities Boosts Sagimet Biosciences (NASDAQ:SGMT) Price Target to $47.00JMP Securities boosted their price target on shares of Sagimet Biosciences from $31.00 to $47.00 and gave the stock a "market outperform" rating in a research report on Monday.January 22, 2024 | marketwatch.comSagimet Biosciences Shares Rise Premarket on NASH Study ResultsJanuary 22, 2024 | markets.businessinsider.comSagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASHJanuary 22, 2024 | markets.businessinsider.comSagimet Biosciences Reports Positive Topline Results From Phase 2b FASCINATE-2 Study Of DenifanstatJanuary 22, 2024 | msn.comSagimet Bio surges after mid-stage win for NASH drugJanuary 22, 2024 | msn.comWhy Is Fatty Liver Disease Focused Sagimet Biosciences Stock Shooting Higher Today? Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address With revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radar (Ad)Revolutionizing communication is what this NASDAQ-traded next-gen solution provider is doing. See how this company is well-positioned to capitalize in 2024 SGMT Media Mentions By Week SGMT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMT News Sentiment▼1.230.56▲Average Medical News Sentiment SGMT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMT Articles This Week▼12▲SGMT Articles Average Week Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: I-Mab News Today Regulus Therapeutics News Today CervoMed News Today Skye Bioscience News Today InterCure News Today PDS Biotechnology News Today CytomX Therapeutics News Today Repare Therapeutics News Today Seres Therapeutics News Today Adicet Bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMT) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
